English
Contact Us
pipeline3.png 手机端pipeline3.png

Pipeline

  • Complement-Mediated Diseases

    IgAN, C3G, IC-MPGN, PNH, and aHUS are severe kidney and hematologic diseases in which dysregulated complement activation plays a central role in disease pathogenesis. This dysregulation can lead to uncontrolled inflammation, tissue injury, hemolysis, thrombosis, and organ damage, including progression to end-stage kidney disease in renal indications. Although complement-targeted therapies have improved clinical outcomes for many patients, significant unmet medical needs remain. RNAi therapies targeting the messenger RNA (mRNA) of complement component 3 (SGB-9768) or complement factor B (SGB-3383) are designed to reduce hepatic production of key complement proteins and thereby modulate complement activation. This approach aims to reduce complement-mediated tissue injury and improve outcomes across complement-mediated kidney and hematologic diseases.

    疾病领域01.jpg

  • Cardiovascular Diseases

    Hypertension and dyslipidemia are major risk factors for cardiovascular disease, contributing to vascular injury, atherosclerosis, and adverse cardiovascular outcomes. Despite major advances in treatment, important unmet needs remain, including poor long-term adherence, suboptimal disease control, and persistent residual cardiovascular risk. RNAi therapy offers a mechanism-based approach by enabling durable silencing of disease-driving genes, such as angiotensinogen (AGT; SGB-3908), with the potential to improve the long-term management of chronic cardiovascular diseases. For multifactorial disorders such as dyslipidemia, bispecific siRNAs are designed to simultaneously target complementary disease pathways and may provide broader lipid-lowering effects through modulation of complementary pathways, as exemplified by our SGB-BS01 (PCSK9/ANGPTL3) and SGB-BS02 (PCSK9/LPA) programs.

    疾病领域02.jpg

  • Obesity and Metablic Diseases

    More than 1 billion people worldwide live with obesity, a major risk factor for over 20 diseases, including diabetes, cardiovascular and neurological disorders. While GLP-1-based therapies provide a treatment option, they can cause gastrointestinal side effects, muscle loss, and weight rebound after discontinuation. RNAi therapy, conversely, precisely targets the mRNA of specific genes involved in metabolic pathways—including INHBE (SGB-7342), and other novel first-in-class targets. RNAi has potential to become a central component of obesity therapy. It drives selective fat loss, preserves lean muscle mass, and improves overall metabolic health.

    疾病领域03(1).jpg

Pipeline: Leveraging Industry-Leading RNAi Technology to Impact Our Core Therapeutic Areas

  • Autoimmune

    Swipe left to show more

    Compound
    Target
    Target Tissue
    Indication(s)
    Preclinical Phase 1 Phase 2 Phase 3
    Rights
    Partners
    SGB-9768
    C3
    Liver
    IgAN
    Global
    C3G/IC-MPGN
    Global
    PNH
    Global
    aHUS
    Global
    SGB-3383
    CFB
    Liver
    Complement-mediated diseases
    Global
    SGB-IM03
    MST1
    Liver
    COPD/Others
    Global

  • Cardiovascular

    Swipe left to show more

    Compound
    Target
    Target Tissue
    Indication(s)
    Preclinical Phase 1 Phase 2 Phase 3
    Rights
    Partners
    SGB-3908
    AGT
    Liver
    Hypertension
    Ex-Asia
    SGB-BS01
    PCSK9+ANGPTL3
    Liver
    Dyslipidemia
    Global
    SGB-BS02
    PCSK9+LPA
    Liver
    Dyslipidemia
    Global
    SGB-CV01
    PLN
    Heart
    Cardiomyopathy
    Global

  • Metabolic/Obesity

    Swipe left to show more

    Compound
    Target
    Target Tissue
    Indication(s)
    Preclinical Phase 1 Phase 2 Phase 3
    Rights
    Partners
    SGB-7342
    INHBE
    Liver
    Obesity
    Global
    SGB-ME02
    Undisclosed
    Undisclosed
    Metabolic
    Royalty-Based
    SGB-6759
    Undisclosed
    Adipose
    Obesity
    Global
    SGB-OB04
    ACVR2
    Sk. Muscle
    Obesity/Others
    Global
    SGB-OB06
    Undisclosed
    Adipose/Liver
    Obesity
    Global
    SGB-OB07
    Undisclosed
    Adipose
    Obesity
    Global

  • Coagulopathies

    Swipe left to show more

    Compound
    Target
    Target Tissue
    Indication(s)
    Preclinical Phase 1 Phase 2 Phase 3
    Rights
    Partners
    SGB-3252
    PLG
    Liver
    HHT, HMB
    Global
Notes:

Phase 2 and Phase 3 trials in Asia will be conducted by Innovent and Phase 3 trials in the rest of the world will be conducted by SanegeneBio.

*IgAN: IgA Nephropathy; C3G:C3 Glomerulopathy; IC-MPGN: Immune Complex-Mediated Membranoproliferative Glomerulonephritis; aHUS: atypical Hemolytic Uremic Syndrome; PNH: Paroxysmal Nocturnal Hemoglobinuria; COPD: Chronic Obstructive Pulmonary Disease; HHT: Hereditary Hemorrhagic Telangiectasia; HMB: Heavy Menstrual Bleeding.